Entropy Technologies LP Purchases Shares of 118,024 Abbott Laboratories $ABT

Entropy Technologies LP purchased a new stake in Abbott Laboratories (NYSE:ABT) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 118,024 shares of the healthcare product maker’s stock, valued at approximately $14,787,000. Abbott Laboratories comprises about 0.8% of Entropy Technologies LP’s investment portfolio, making the stock its 6th largest position.

Other hedge funds also recently added to or reduced their stakes in the company. MidAtlantic Capital Management Inc. purchased a new position in Abbott Laboratories in the fourth quarter valued at approximately $25,000. Harbor Capital Advisors Inc. purchased a new position in Abbott Laboratories in the fourth quarter valued at approximately $27,000. Intesa Sanpaolo Wealth Management purchased a new position in Abbott Laboratories in the fourth quarter valued at approximately $29,000. Prudent Man Investment Management Inc. purchased a new position in shares of Abbott Laboratories during the fourth quarter worth approximately $33,000. Finally, Leonteq Securities AG purchased a new position in shares of Abbott Laboratories during the fourth quarter worth approximately $35,000. 75.18% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of equities analysts have recently issued reports on ABT shares. Sanford C. Bernstein lowered their target price on shares of Abbott Laboratories from $125.00 to $110.00 and set an “outperform” rating on the stock in a research report on Friday, April 17th. Stifel Nicolaus lowered their target price on shares of Abbott Laboratories from $145.00 to $120.00 and set a “buy” rating on the stock in a research report on Friday, April 17th. Oppenheimer lowered their target price on shares of Abbott Laboratories from $132.00 to $115.00 and set an “outperform” rating on the stock in a research report on Friday, April 17th. UBS Group lowered their target price on shares of Abbott Laboratories from $158.00 to $135.00 and set a “buy” rating on the stock in a research report on Monday, April 20th. Finally, Wells Fargo & Company lowered their target price on shares of Abbott Laboratories from $122.00 to $109.00 and set an “overweight” rating on the stock in a research report on Friday, April 17th. Two research analysts have rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and five have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, Abbott Laboratories currently has an average rating of “Moderate Buy” and an average target price of $118.38.

Insider Buying and Selling at Abbott Laboratories

In related news, CFO Philip P. Boudreau purchased 2,200 shares of the firm’s stock in a transaction that occurred on Thursday, April 23rd. The stock was purchased at an average cost of $91.50 per share, with a total value of $201,300.00. Following the completion of the acquisition, the chief financial officer directly owned 2,200 shares in the company, valued at $201,300. This trade represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is accessible through this link. Also, Director Daniel J. Starks purchased 10,000 shares of the firm’s stock in a transaction that occurred on Monday, April 27th. The shares were bought at an average cost of $92.65 per share, with a total value of $926,500.00. Following the completion of the acquisition, the director owned 6,751,103 shares of the company’s stock, valued at approximately $625,489,692.95. This trade represents a 0.15% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. 0.46% of the stock is owned by company insiders.

Trending Headlines about Abbott Laboratories

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: Abbott declared its 410th consecutive quarterly dividend, underscoring its long track record of returning cash to shareholders. The board approved a 63-cent per share quarterly dividend. Abbott declares 410th consecutive quarterly dividend
• Positive Sentiment: Erste Group Bank nudged its FY2026 EPS estimate higher for Abbott, aligning with the current consensus of $5.48 per share, which suggests analysts still see stable earnings power.
• Positive Sentiment: Abbott also continues to highlight growth opportunities in diabetes care and medtech, including an expanded MiniMed collaboration and recent CE Mark approval for Libre Duo, supporting the company’s innovation story.
• Neutral Sentiment: Research coverage remains mixed, with one Seeking Alpha piece calling Abbott “structurally undervalued,” but this is opinion-based and not a direct catalyst. Abbott Laboratories Remains Structurally Undervalued
• Neutral Sentiment: Erste Group also trimmed its FY2027 EPS estimate slightly to $6.04 from $6.05, a very small revision that should have limited impact on sentiment.
• Neutral Sentiment: Star51 Capital’s first close of its medtech fund included Abbott as a lead backer, reinforcing Abbott’s strategic interest in healthcare innovation, though the direct stock impact is likely modest.
• Negative Sentiment: BofA cut its price target on Abbott from $120 to $102, signaling less upside than before and likely adding to investor caution. BofA adjusts price target on Abbott Laboratories to 102 from 120
• Negative Sentiment: Recent trading has shown Abbott slipping more than the broader market, reflecting ongoing weakness in the shares and investor concern over valuation versus slower near-term momentum. Abbott (ABT) Dips More Than Broader Market
• Negative Sentiment: Portfolio filings showing Elfun Trusts exited Abbott may also add a small amount of selling pressure, though this is not a major fundamental development. Elfun Trusts Exits Abbott Laboratories

Abbott Laboratories Price Performance

Shares of NYSE ABT opened at $87.89 on Friday. The company has a debt-to-equity ratio of 0.56, a current ratio of 1.39 and a quick ratio of 1.01. The stock has a fifty day moving average price of $91.46 and a 200 day moving average price of $107.98. Abbott Laboratories has a 1-year low of $81.97 and a 1-year high of $139.06. The company has a market cap of $153.08 billion, a PE ratio of 24.62, a P/E/G ratio of 1.47 and a beta of 0.63.

Abbott Laboratories (NYSE:ABT) last issued its quarterly earnings results on Thursday, April 16th. The healthcare product maker reported $1.15 earnings per share for the quarter, topping the consensus estimate of $1.14 by $0.01. Abbott Laboratories had a return on equity of 17.62% and a net margin of 13.90%.The firm had revenue of $11.16 billion during the quarter, compared to the consensus estimate of $10.99 billion. During the same period last year, the company earned $1.09 earnings per share. The company’s revenue for the quarter was up 7.8% on a year-over-year basis. Abbott Laboratories has set its FY 2026 guidance at 5.380-5.580 EPS and its Q2 2026 guidance at 1.250-1.310 EPS. Sell-side analysts forecast that Abbott Laboratories will post 5.48 EPS for the current year.

About Abbott Laboratories

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.